General MedicationsINTRAVENOUSStandard
CONTEPO
FOSFOMYCIN DISODIUM
Standard Dose
EQ 6GM BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview CONTEPO is listed in Drugs@FDA under application 212271 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient FOSFOMYCIN DISODIUM Form and strength POWDER;INTRAVENOUS - EQ 6GM BASE/VIAL Sponsor MEITHEAL Submission history Latest submission status date: 2025-10-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview CONTEPO is listed in Drugs@FDA under application 212271 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient FOSFOMYCIN DISODIUM Form and strength POWDER;INTRAVENOUS - EQ 6GM BASE/VIAL Sponsor MEITHEAL Submission history Latest submission status date: 2025-10-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.